Of these patients, 613 patients had advanced-stage disease, of which 136 (22%) patients had cEGFRm at diagnosis, 8 (1%) had ex20ins at diagnosis, 338 (55%) had EGFR wild type tumours at diagnosis, and 131 (21%) did not have mutation testing at diagnosis conducted at the UHN-PMCC. This evidence concerns the gene EGFR and neoplasm.